Baxter

BAX

Chicago, United States· Est. 1931

baxter.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

BAX · Stock Price

USD 17.49-13.71 (-43.94%)

Market Cap: $9.0B

Historical price data

Market Cap: $9.0BPipeline: 132 drugs (34 Phase 3)Patents: 20Founded: 1931Employees: 50,000-60,000HQ: Chicago, United States

Sector Ranking#31 in Digital Health & Biotech SaaS #110 in Small Molecule Drugs

Overview

Baxter International Inc. is a multinational healthcare corporation with a 90-year heritage, dedicated to saving and sustaining lives through a diversified portfolio of medical devices, pharmaceuticals, and connected care solutions. The company's strategy centers on addressing healthcare's connectivity gap by integrating hardware, software, and clinical workflows to improve efficiency and patient outcomes across hospital, home, and alternative care settings. Facing a challenging market environment, Baxter is navigating a strategic transformation to streamline its portfolio, reduce debt, and leverage its broad global footprint to capitalize on the growing demand for integrated, data-driven healthcare.

Renal CareCritical CareNutritionSurgical CareMedication Delivery

Technology Platform

A connected care platform integrating medical devices, software, and clinical workflows to solve healthcare's data silo challenge, enabling automated medication safety, remote patient monitoring, and streamlined clinical operations.

Pipeline

132

132 drugs in pipeline34 in Phase 3

Drug	Indication	Stage
Fibrin Sealant (Tisseel) used in the Experimental Arm.	Malignant Melanoma	Approved
Sevoflurane + propofol + remifentanil	Intra-abdominal and Intrapelvic Surgery	Approved
Physioneal + Dianeal + Extraneal + Nutrineal	ESRD	Approved
Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution	Peritoneal Dialysis	Approved
Clinolipid + Intralipid	Essential Fatty Acid Deficiency (EFAD)	Approved

FDA Approved Drugs

PHYTONADIONEANDAFeb 26, 2026

KETAMINE HYDROCHLORIDEANDASep 17, 2025

HYDRALAZINE HYDROCHLORIDEANDAJul 17, 2025

Opportunities

Significant opportunities exist in the global shift to home-based care and the digital transformation of healthcare.

Baxter's broad portfolio in renal care, nutrition, and respiratory therapy, coupled with its push into connected devices and data platforms, positions it to capitalize on these long-term, structural trends aimed at improving outcomes and reducing system costs.

Risk Factors

Key risks include execution challenges related to the recent spin-off of its renal care business and associated debt reduction goals, intense pricing pressure across its generic pharmaceuticals and device segments, and macroeconomic headwinds affecting hospital capital spending and supply chain costs.

Failure to successfully commercialize its connected health initiatives would also impair growth and margin improvement plans.

Competitive Landscape

Baxter operates in highly competitive, fragmented markets, facing giants like Fresenius and DaVita in renal care, BD and ICU Medical in medication delivery, and a host of generic drug manufacturers. Its competitive edge lies in its integrated portfolio and deep hospital relationships, though it faces constant pressure from low-cost rivals and must innovate to maintain share.